Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

821
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

738
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.2K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Arthritis care & research·2026
Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026
Same author

Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score.

Annals of the rheumatic diseases·2026
Same author

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133).

Annals of the rheumatic diseases·2026
Same author

A rare presentation of the diffuse dermal mucinosis in adenocarcinoma of the lungs treated with pembrolizumab and pemetrexed.

JAAD case reports·2025
Same author

Hospitalizations in patients with systemic sclerosis: Differences between limited and diffuse cutaneous subtypes.

Journal of scleroderma and related disorders·2024

Related Experiment Video

Updated: Apr 18, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

Fiona M McQueen1, Kamal Solanki2

  • 1Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Department of Rheumatology, Greenlane Clinical Centre, Auckland District Health Board, Auckland, Department of Rheumatology, Waikato Hospital and Waikato Clinical School, University of Auckland, Hamilton, New Zealand Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Department of Rheumatology, Greenlane Clinical Centre, Auckland District Health Board, Auckland, Department of Rheumatology, Waikato Hospital and Waikato Clinical School, University of Auckland, Hamilton, New Zealand f.mcqueen@auckland.ac.nz.

Rheumatology (Oxford, England)
|January 10, 2015
PubMed
Summary

B-cell depletion therapy, such as rituximab, shows promise in slowing systemic sclerosis (SSc) progression, particularly skin thickening and lung fibrosis in early diffuse SSc (dcSSc). Further research is needed to confirm these preliminary findings.

Keywords:
B-cell depletiondiffuse cutaneous systemic sclerosisrituximab

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K

Area of Science:

  • Rheumatology and Immunology
  • Fibrosis Research
  • Autoimmune Diseases

Background:

  • Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by fibrosis.
  • B cells and autoantibodies are implicated as key drivers of fibrosis in SSc.
  • Existing treatments for SSc have limited efficacy in halting disease progression.

Purpose of the Study:

  • To review the clinical and basic science evidence for rituximab therapy in SSc.
  • To explore the role of B cells in SSc pathogenesis.
  • To compare SSc with other connective tissue diseases (CTDs) where B-cell depletion is effective.

Main Methods:

  • Review of observational case-control study data from the European League Against Rheumatism Scleroderma Trials and Research group.
  • Analysis of clinical evidence for rituximab's therapeutic use in SSc.
  • Examination of basic science evidence on B cells and autoantibodies in fibrosis.

Main Results:

  • Preliminary data suggest rituximab may reduce skin thickening and lung fibrosis progression in SSc patients.
  • Evidence indicates potential efficacy in a subgroup with early diffuse SSc (dcSSc).
  • B cells and autoantibodies are identified as primary drivers of skin and lung fibrosis.

Conclusions:

  • B-cell depletion therapy, including rituximab, presents a potential therapeutic strategy for SSc.
  • Further cautious investigation is warranted, considering spontaneous regression in early disease.
  • Parallels exist between SSc and other CTDs responsive to B-cell depletion therapy.